MINTZ STEVEN

Director Steven Mintz buys 6,000 shares of Serina Therapeutics at $6.47; stock -57.4% from 52-week high.

Steven Mintz, a Director, purchased 6,000 shares at $6.47 on 2024-09-12, expanding his holdings by 52.4% to 17.4K shares. The stock has declined 11.2% over the preceding 30 days and 45.3% over 90 days, trading at $6.34—well below its 52-week high of $14.87. Within this same ticker, Mintz made five prior purchases on 2024-08-15, all showing a -2.3% return at the 30-day mark; longer-term outcomes remain unmeasurable for those trades. His cross-ticker track record shows zero wins at the 90-day mark across 13 prior buys despite an average 30-day gain of 8.7%, underscoring a pattern of poor timing. The company reported recent quarterly revenue of $51.0K with positive net income of $5.2M, but full-year net income was negative despite 317.6% annual revenue growth, suggesting operational or accounting volatility. This purchase timing—adding to a depressed position amid sustained downward momentum—lacks supporting evidence from the insider's historical execution pattern.

Director MINTZ STEVEN bought 8,943 shares at $6.59 on 2024-08-15 ($58.9K); stock now $8.09, up from lows but -45.6% from 52-week high.

MINTZ STEVEN executed 5 separate purchases totaling 8,943 shares for $58,928.12 at $6.59 on 2024-08-15, moving from a short position (-6,293 shares) to a 2,650-share long position. The purchases occurred while the stock trades at $8.09, up 22.8% from the transaction price but 45.6% below its 52-week high of $14.87. His prior trades at Serina Therapeutics show a 0% win rate at the 90-day horizon (all five prior buys resulted in losses by day 90), and his cross-ticker track record shows a 0.00% 90-day win rate across 8 buys, with average 90-day returns of -21.8%. The company posted strong revenue growth of +317.6% year-over-year but was unprofitable over its most recent full fiscal year, suggesting business expansion into losses rather than profitability gains.

Director Mintz buys 7,600 shares in 2 tranches for $70,900 avg $9.33, raising stake 229.8%; stock -42.4% from 52-week high, -36.4% in 90 days.

Steven Mintz, as Director, executed 2 purchases totaling 7,600 shares for $70,900.00 between June 21–25, 2024, at prices of $9.50 and $9.00. This increased his holdings by 229.8% from 3,307 to 10,907 shares, representing a substantial accumulation over a compressed timeframe. The timing occurred as the stock trades -42.4% from its 52-week high and has declined -36.4% over the prior 90 days, placing these acquisitions in a sharp downtrend. His prior 5 trades at Serina (all in May) each posted positive 30-day returns (+5.5% to +23.1%), yet the current price of $8.56 sits below both transaction prices, representing immediate underwater positions; neither buying window has yet to show gains. For a company with $5,000.00 quarterly revenue, $-9,437,000.00 net income, and market cap of $72,022,889.84, the purchase quantity and timing merit scrutiny regarding whether it reflects conviction in a turnaround or exposure to deteriorating fundamentals during a liquidity event.